Airway disease is on the rise. Asthma is the most common chronic childhood condition, and Chronic Obstructive Pulmonary Disease (COPD), is the fourth leading cause of death in America. Research is underway both to identify risks and to develop therapeutic clinical trials.
A unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global biologics R&D arm, MedImmune), and Foundation Medicine has launched the Lung Cancer Master Protocol (Lung-MAP) trial.
Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease that makes it difficult for sufferers to breathe, causing coughing, wheezing, shortness of breath and other symptoms. Affecting as many as 24 million people in the United States, the disease gradually worsens over time and is currently without a cure. Existing treatments can provide only moderate relief of symptoms. Spiromics aims to accelerate the development of new therapies for COPD through the collection and analysis of phenotypic, genetic, proteomic and clinical data from 3,000 individuals with COPD to better identify subpopulations and intermediate outcome measures to help guide more personalized monitoring and therapeutic interventions.